Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension

Journal of Pharmacology and Experimental Therapeutics(2021)10.1124/jpet.121.000525Source: DataRank Database

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension is a research paper published in Journal of Pharmacology and Experimental Therapeutics (2021). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.52)OA: hybridTopics (22)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Sean E. Thatcher ORCID,Ching L Liang,Heba Ali ORCID,Mark Ensor ORCID,Lisa A. Cassis ORCID

Live enrichment

PubMed:33707301 PMC:PMC8140395 OpenAlex:https://openalex.org/W3134088451

NHLBI NIH HHS

Grant: R01 HL107326

FWCI

0.52

Citation Percentile

0.6%

Citation Trend

2021

2022

2024

2026

hybridLicense: cc-by

journalhttps://jpet.aspetjournals.org/article/S0022-3565(24)27677-1/pdf

publisherhttps://jpet.aspetjournals.org/article/S0022-3565(24)27677-1/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0022356524276771?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022356524276771?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/jpet.121.000525

Fields of Study

Aortic aneurysm repair treatmentsCardiac, Anesthesia and Surgical OutcomesBlood Pressure and Hypertension Studies

MeSH Terms

AminobutyratesAngiotensin IIAnimalsAntihypertensive AgentsBiphenyl CompoundsNeprilysinAtherosclerosisMice

Keywords

ValsartanSacubitrilAngiotensin IIMedicineInternal medicineSacubitril, ValsartanBlood pressureEndocrinologyRenin–angiotensin systemPharmacologyHeart failure

Sustainable Development Goals

SDG 0: Good health and well-being